Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [147]

Management of infection risk to myeloma patients during the COVID pandemic

Prof Heinz Ludwig - Wilhelminenspital, Center for Oncology and Hematology...

Management of infection risk to myeloma patients during the COVID pandemic ( Prof Heinz Ludwig - Wilhelminenspital, Center for Oncology and Hematology, Vienna, Austria )

Lenalidomide combination for multiple myeloma

Prof Xavier Leleu - Hôpital La Mileterie CHU, Poitiers, France

Lenalidomide combination for multiple myeloma ( Prof Xavier Leleu - Hôpital La Mileterie CHU, Poitiers, France )

Mass spectrometry for the detection of minimal residual disease (MRD) in myeloma

Dr Noemí Puig - Hospital Universitario de Salamanca, Salamanca, Spain

Mass spectrometry for the detection of minimal residual disease (MRD) in myeloma ( Dr Noemí Puig - Hospital Universitario de Salamanca, Salamanca, Spain )

Latest updates to the ESMO bone health guidelines

Prof Robert Coleman - University of Sheffield, Sheffield, UK

Latest updates to the ESMO bone health guidelines ( Prof Robert Coleman - University of Sheffield, Sheffield, UK )

Exploring TKIs in metastatic sarcomas: Results of REGOBONE osteosarcoma cohort

Professor Jean-Yves Blay and Professor Florence Duffaud

Exploring TKIs in metastatic sarcomas: Results of REGOBONE osteosarcoma cohort ( Professor Jean-Yves Blay and Professor Florence Duffaud )

D-VTd in transplant-eligible newly diagnosed MM: Subgroup analysis of high-risk...

Prof Pieter Sonneveld - Erasmus MC Cancer Institute, Rotterdam, Netherlands

D-VTd in transplant-eligible newly diagnosed MM: Subgroup analysis of high-risk patients in CASSIOPEIA ( Prof Pieter Sonneveld - Erasmus MC Cancer Institute, Rotterdam, Netherlands )

A phase 1b study of once-weekly KRd in patients with newly diagnosed multiple...

Prof Ola Landgren - Memorial Sloan Kettering Cancer Center, New York City, USA

A phase 1b study of once-weekly KRd in patients with newly diagnosed multiple myeloma ( Prof Ola Landgren - Memorial Sloan Kettering Cancer Center, New York City, USA )

Synthesis, preclinical analysis, and first-inhuman phase I imaging of 89Zr...

Prof Ola Landgren - Memorial Sloan Kettering Cancer Center, New York City, USA

Synthesis, preclinical analysis, and first-inhuman phase I imaging of 89Zr-DFOdaratumumab for CD38 targeted imaging of myeloma ( Prof Ola Landgren - Memorial Sloan Kettering Cancer Center, New York City, USA )

Comparative effectiveness of lenalidomide, bortezomib, and their combinations...

Dr Peter Barth - Rhode Island Hospital, Philadelphia, USA

Comparative effectiveness of lenalidomide, bortezomib, and their combinations for elderly myeloma patients ( Dr Peter Barth - Rhode Island Hospital, Philadelphia, USA )

Twice-weekly vs once-weekly Krd in early relapsed refractory multiple myeloma

Prof Xavier Leleu - CHU la Miletrie, Poitiers, France

$Twice-weekly vs once-weekly Krd in early relapsed refractory multiple myeloma ( Prof Xavier Leleu - CHU la Miletrie, Poitiers, France )$

Maintenance with weekly carfilzomib in elderly newly diagnosed multiple myeloma

Prof Xavier Leleu - CHU la Miletrie, Poitiers, France

Maintenance with weekly carfilzomib in elderly newly diagnosed multiple myeloma ( Prof Xavier Leleu - CHU la Miletrie, Poitiers, France )

Real-world use of carfilzomib therapy among patients with existing...

Prof Xavier Leleu - CHU la Miletrie, Poitiers, France

Real-world use of carfilzomib therapy among patients with existing cardiovascular medical history ( Prof Xavier Leleu - CHU la Miletrie, Poitiers, France )

More from ecancer